60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares Up 2.7%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares shot up 2.7% during trading on Friday . The stock traded as high as $0.24 and last traded at $0.24. 84,376 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 290,194 shares. The stock had previously closed at $0.23.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, April 3rd.

60 Degrees Pharmaceuticals Price Performance

The stock’s 50-day moving average price is $0.27 and its 200-day moving average price is $0.55.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.44) earnings per share (EPS) for the quarter. The company had revenue of ($0.10) million during the quarter, compared to analyst estimates of $0.06 million. On average, research analysts anticipate that 60 Degrees Pharmaceuticals, Inc. will post -0.29 earnings per share for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.